BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,235,868 | -26.2% | 32,747 | -11.0% | 0.02% | -20.7% |
| Q2 2023 | $1,675,540 | +15.2% | 36,777 | +2.5% | 0.03% | -3.3% |
| Q1 2023 | $1,454,934 | +13.9% | 35,871 | +43.1% | 0.03% | +7.1% |
| Q4 2022 | $1,277,607 | -4.2% | 25,066 | +1.2% | 0.03% | -9.7% |
| Q3 2022 | $1,334,000 | -77.8% | 24,767 | -73.6% | 0.03% | -76.3% |
| Q2 2022 | $6,015,000 | -20.0% | 93,647 | -3.4% | 0.13% | -1.5% |
| Q1 2022 | $7,517,000 | -10.6% | 96,940 | -1.1% | 0.13% | -8.3% |
| Q4 2021 | $8,412,000 | -0.1% | 97,993 | -6.4% | 0.14% | -6.5% |
| Q3 2021 | $8,419,000 | -9.5% | 104,669 | -9.4% | 0.16% | -7.7% |
| Q2 2021 | $9,300,000 | -0.9% | 115,529 | +3.8% | 0.17% | -6.1% |
| Q1 2021 | $9,387,000 | +5.8% | 111,295 | +0.7% | 0.18% | -0.6% |
| Q4 2020 | $8,871,000 | -10.5% | 110,555 | -10.3% | 0.18% | -23.4% |
| Q3 2020 | $9,908,000 | -12.1% | 123,201 | -5.9% | 0.24% | -15.5% |
| Q2 2020 | $11,269,000 | +5.3% | 130,885 | -0.7% | 0.28% | -14.5% |
| Q1 2020 | $10,706,000 | +2.5% | 131,866 | +5.5% | 0.32% | +41.9% |
| Q4 2019 | $10,448,000 | +10.7% | 124,945 | +15.8% | 0.23% | +3.2% |
| Q3 2019 | $9,434,000 | +6.3% | 107,853 | -0.4% | 0.22% | +6.7% |
| Q2 2019 | $8,871,000 | +0.1% | 108,309 | -0.6% | 0.21% | +4.0% |
| Q1 2019 | $8,860,000 | +16.2% | 108,960 | -5.9% | 0.20% | +1.5% |
| Q4 2018 | $7,623,000 | -16.1% | 115,810 | -1.8% | 0.20% | +4.2% |
| Q3 2018 | $9,087,000 | +2.7% | 117,875 | -1.6% | 0.19% | +3.8% |
| Q2 2018 | $8,849,000 | +14.1% | 119,841 | +0.5% | 0.18% | +19.7% |
| Q1 2018 | $7,757,000 | -22.9% | 119,257 | -23.4% | 0.15% | -21.2% |
| Q4 2017 | $10,064,000 | +2.4% | 155,692 | -0.6% | 0.19% | +6.6% |
| Q3 2017 | $9,829,000 | +4.1% | 156,638 | +0.4% | 0.18% | 0.0% |
| Q2 2017 | $9,441,000 | +18.9% | 155,949 | +1.9% | 0.18% | +19.1% |
| Q1 2017 | $7,938,000 | +188.4% | 153,069 | +146.6% | 0.15% | +171.4% |
| Q4 2016 | $2,752,000 | -8.9% | 62,074 | -2.2% | 0.06% | -8.2% |
| Q3 2016 | $3,020,000 | -20.3% | 63,438 | -24.3% | 0.06% | -25.6% |
| Q2 2016 | $3,791,000 | +2.0% | 83,824 | -7.4% | 0.08% | +2.5% |
| Q1 2016 | $3,717,000 | +6.3% | 90,483 | -1.3% | 0.08% | +9.6% |
| Q4 2015 | $3,498,000 | +10.1% | 91,678 | -5.2% | 0.07% | +4.3% |
| Q3 2015 | $3,178,000 | -54.6% | 96,740 | -3.3% | 0.07% | -46.2% |
| Q2 2015 | $6,995,000 | -4.7% | 100,033 | -6.7% | 0.13% | -5.1% |
| Q1 2015 | $7,342,000 | -9.6% | 107,177 | -3.3% | 0.14% | -13.8% |
| Q4 2014 | $8,124,000 | +12.8% | 110,851 | +10.5% | 0.16% | +8.2% |
| Q3 2014 | $7,200,000 | -0.3% | 100,324 | +0.4% | 0.15% | +4.3% |
| Q2 2014 | $7,222,000 | -4.3% | 99,895 | -2.6% | 0.14% | -4.1% |
| Q1 2014 | $7,543,000 | +7.5% | 102,521 | +1.6% | 0.15% | +7.3% |
| Q4 2013 | $7,019,000 | +16.2% | 100,927 | +9.8% | 0.14% | +9.6% |
| Q3 2013 | $6,041,000 | +3.2% | 91,959 | +8.8% | 0.12% | -5.3% |
| Q2 2013 | $5,853,000 | – | 84,495 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |